Katsuaki Maehara: TTF-1 is a New Marker to Identify Patients Best Suited for Lung Cancer KRAS Inhibitors
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X about a recent paper shared by Ferdinandos Skoulidis et al. published in Nature:
“TTF-1 is a new marker to identify patients best suited for lung cancer KRAS inhibitors
Sotorasib – KRAS G12C mut
Lung cancer patients with high TTF-1 expression had improved survival outcomes after treatment with the KRAS inhibitor Sotrasib.
This biomarker may help identify patients who will benefit most from Sotrasib and those who need alternative or combination therapies.
TTF-1 is an easily accessible biomarker commonly used to diagnose lung cancer.”
Title: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Authors: Ferdinandos Skoulidis, Bob T. Li, Adrianus Johannes de Langen, David S. Hong, Herve Lena, Juergen Wolf, Grace K. Dy, Alessandra Curioni Fontecedro, Pascale Tomasini, Vamsidhar Velcheti, Anthonie J. van der Wekken, Christophe Dooms, Luis Paz-Ares Rodriguez, Giannis Mountzios, Adrian Sacher, Ernest Nadal, Sebastien Couraud, Sang-We Kim, Kenneth O’Byrne, Danilo Rocco, Ryo Toyozawa, Izabela Chmielewska, Colin R. Lindsay, Antreas Hindoyan, Lata Mukundan, Tomasz Wilmanski, Abraham Anderson, Christine Ardito-Abraham, Amrita Pati, Anita Reddy, Bhakti Mehta and Martin Schuler
More posts featuring Katsuaki Maehara.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023